BAT-90 A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’
- Coordinator
- Betaglue Therapeutics SpA, Italy
- Runs
- 1 April 2024 to 31 December 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €7.1m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101164662
What the project is doing
In the project's own words, from its summary on CORDIS.
BetaGlue is developing an innovative ""radiotherapy from within"", personalized and cost-effective anti-tumoural platform technology called BAT-90. BAT-90 maximises the therapeutic index of loco-regional treatment by eliminating off-target radiation dose in a simple and easy to use product. The product aims to provide a radiotherapeutic treatment option for a range of solid tumour types including: unresectable hepatocellular carcinoma (HCC) and locally advanced and borderline resectable pancreatic cancer (PDAC) patients, where in the first-line setting, there exists a major unmet clinical need.
Through the percutaneous administration of BAT-90 under radiological guidance (usually ultrasound) BAT-90 overcomes the accessibility and off-target side effect limitations of external beam radiotherapy, forms of brachytherapy, proton beam radiotherapy trans-arterial radio-embolisation and microwave ablation. BAT-90 has already demonstrated safety and preliminary effectiveness in first-in-human clinical studies.""
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Betaglue Therapeutics SpA | Milano | Italy | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI